What is TB-500?
TB-500 is a synthetic fragment related to thymosin beta-4, a naturally occurring protein involved in cell migration and repair. It is marketed for wound healing and recovery. It is not approved as a medicine in the US.
What the evidence shows
Evidence for TB-500 is largely from animal and laboratory studies; controlled human trials for the marketed uses are lacking. The FDA placed it in Category 2 in 2023 over concerns including impurities and insufficient human safety data, so efficacy in people is unproven and its long-term safety is not established.
Is it legal?
TB-500 is not FDA-approved. In April 2026 it was removed from FDA Category 2 but not moved to the approved Category 1 list, so legal compounding is not authorized; the PCAC reviews it on July 23, 2026.
Will TB-500 become legal in 2026?+
Is “research-grade” TB-500 the same as a medicine?+
Primary sources: FDA 503A interim list (Category 2, 2023) · FDA Advisory Committee Calendar; Federal Register docket FDA-2025-N-6895.
Medical & editorial disclaimer. This article is independent reference information, not medical advice and not a recommendation to use any substance. TB-500 is not FDA-approved. Nothing here should be used to obtain, prepare, or self-administer any drug. Talk to a licensed clinician about your health. Peptide Docket is not affiliated with the FDA and does not sell peptides.